Adolescent Male Human Papillomavirus Vaccination
Objective . To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods . We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-04-01
|
| Series: | Global Pediatric Health |
| Online Access: | https://doi.org/10.1177/2333794X16642373 |
| _version_ | 1818187663938682880 |
|---|---|
| author | Vivian C. Nanagas MD, MSc Adrienne Stolfi MSPH Maria T. Nanagas MD Gregory M. Eberhart MD Sherman J. Alter MD |
| author_facet | Vivian C. Nanagas MD, MSc Adrienne Stolfi MSPH Maria T. Nanagas MD Gregory M. Eberhart MD Sherman J. Alter MD |
| author_sort | Vivian C. Nanagas MD, MSc |
| collection | DOAJ |
| description | Objective . To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods . We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to national recommendations and followed-up for HPV4 series completion rates. After national recommendation, 248 urban clinic and 247 suburban clinic males were reviewed for HPV4-1 uptake. Factors associated with HPV4-1 refusal were determined with multiple logistic regression. Results . Of the initial 292 males, 78% received HPV4-1 and 38% received the 3-dose series. After recommendation, HPV4-1 uptake was 59% and 7% in urban and suburban clinics, respectively. Variables associated with HPV4-1 uptake/refusal included time period, race, type of insurance, and receipt of concurrent vaccines. Conclusions . HPV4-1 vaccination rates in our urban clinic were high before and after routine HPV vaccine recommendations for adolescent males. Our vaccination rates were much higher than in a suburban practice. |
| first_indexed | 2024-12-11T23:14:37Z |
| format | Article |
| id | doaj.art-0d0f29b84e1a4f9ba1af7663f1430f99 |
| institution | Directory Open Access Journal |
| issn | 2333-794X |
| language | English |
| last_indexed | 2024-12-11T23:14:37Z |
| publishDate | 2016-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Global Pediatric Health |
| spelling | doaj.art-0d0f29b84e1a4f9ba1af7663f1430f992022-12-22T00:46:35ZengSAGE PublishingGlobal Pediatric Health2333-794X2016-04-01310.1177/2333794X1664237310.1177_2333794X16642373Adolescent Male Human Papillomavirus VaccinationVivian C. Nanagas MD, MSc0Adrienne Stolfi MSPH1Maria T. Nanagas MD2Gregory M. Eberhart MD3Sherman J. Alter MD4Wright State University Boonshoft School of Medicine, Dayton, OH, USAWright State University Boonshoft School of Medicine, Dayton, OH, USADayton Children’s Hospital, Dayton, OH, USACornerstone Pediatrics, Springboro, OH, USADayton Children’s Hospital, Dayton, OH, USAObjective . To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods . We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to national recommendations and followed-up for HPV4 series completion rates. After national recommendation, 248 urban clinic and 247 suburban clinic males were reviewed for HPV4-1 uptake. Factors associated with HPV4-1 refusal were determined with multiple logistic regression. Results . Of the initial 292 males, 78% received HPV4-1 and 38% received the 3-dose series. After recommendation, HPV4-1 uptake was 59% and 7% in urban and suburban clinics, respectively. Variables associated with HPV4-1 uptake/refusal included time period, race, type of insurance, and receipt of concurrent vaccines. Conclusions . HPV4-1 vaccination rates in our urban clinic were high before and after routine HPV vaccine recommendations for adolescent males. Our vaccination rates were much higher than in a suburban practice.https://doi.org/10.1177/2333794X16642373 |
| spellingShingle | Vivian C. Nanagas MD, MSc Adrienne Stolfi MSPH Maria T. Nanagas MD Gregory M. Eberhart MD Sherman J. Alter MD Adolescent Male Human Papillomavirus Vaccination Global Pediatric Health |
| title | Adolescent Male Human Papillomavirus Vaccination |
| title_full | Adolescent Male Human Papillomavirus Vaccination |
| title_fullStr | Adolescent Male Human Papillomavirus Vaccination |
| title_full_unstemmed | Adolescent Male Human Papillomavirus Vaccination |
| title_short | Adolescent Male Human Papillomavirus Vaccination |
| title_sort | adolescent male human papillomavirus vaccination |
| url | https://doi.org/10.1177/2333794X16642373 |
| work_keys_str_mv | AT viviancnanagasmdmsc adolescentmalehumanpapillomavirusvaccination AT adriennestolfimsph adolescentmalehumanpapillomavirusvaccination AT mariatnanagasmd adolescentmalehumanpapillomavirusvaccination AT gregorymeberhartmd adolescentmalehumanpapillomavirusvaccination AT shermanjaltermd adolescentmalehumanpapillomavirusvaccination |